重药控股(000950) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥15,878,655,477.15, representing a 9.80% increase compared to ¥14,461,217,356.50 in the same period last year[5] - Net profit attributable to shareholders was ¥111,888,762.43, a 40.70% increase from ¥79,524,791.42 year-on-year[5] - Net profit for the current period was ¥144,327,904.72, compared to ¥133,286,652.92 in the previous period, representing an increase of 8.0%[32] - The net profit attributable to the parent company was ¥111,888,762.43, up from ¥79,524,791.42, indicating a significant growth of 40.6%[35] - The company's diluted earnings per share increased by 20.00% to ¥0.06 from ¥0.05 year-on-year[5] - Earnings per share (basic and diluted) for the current period was ¥0.06, up from ¥0.05 in the previous period[35] Cash Flow - The net cash flow from operating activities was -¥3,159,107,305.23, reflecting a 24.01% increase in outflow compared to -¥2,547,529,457.48 in the previous year[14] - Cash inflow from operating activities totaled 15,384,982,283.54, up from 13,271,781,013.99, reflecting a year-over-year increase of approximately 16.8%[38] - Cash outflow from operating activities increased to 18,544,089,588.77 from 15,819,310,471.47, representing a rise of about 17.3%[38] - The net cash flow from investing activities was 74,238,524.35, a significant improvement from -370,370,973.25 in the previous period[41] - Cash inflow from financing activities was 7,179,947,756.00, slightly down from 7,352,747,582.06, indicating a decrease of approximately 2.3%[41] - The net cash flow from financing activities increased to 2,583,847,229.80 from 2,086,407,203.98, showing a growth of about 23.9%[41] - The ending balance of cash and cash equivalents was 2,929,726,709.54, compared to 1,776,931,901.68 in the previous period, marking an increase of approximately 64.5%[41] Assets and Liabilities - The total assets at the end of the reporting period were ¥52,383,341,339.08, up 5.40% from ¥49,700,081,320.97 at the end of the previous year[5] - Total liabilities increased to ¥40,472,842,190.39 from ¥37,933,537,693.05, marking a rise of 6.4%[27] - The total non-current liabilities amounted to ¥6,806,996,055.93, an increase from ¥6,209,456,696.33, reflecting a growth of 9.6%[27] - The total equity rose to ¥11,910,499,148.69, compared to ¥11,766,543,627.92, reflecting an increase of 1.2%[27] - The company reported a total of 33.67 billion RMB in current liabilities, up from 31.72 billion RMB, indicating an increase of about 6.14%[23] Current Assets and Receivables - The company's accounts receivable increased by 11.53% to ¥28,979,729,992.72, primarily due to the timing of sales and collections[8] - The company's total current assets increased to approximately 43.97 billion RMB from 41.34 billion RMB at the beginning of the year, reflecting a growth of about 6.36%[20] - Accounts receivable increased to approximately 28.98 billion RMB from 25.98 billion RMB, showing a growth of about 11.6%[20] - The company’s inventory rose by 7.41% to ¥6,499,390,715.11, driven by business expansion and increased stockpiling[8] - Inventory rose to approximately 6.50 billion RMB from 6.05 billion RMB, marking an increase of about 7.36%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 65,555[15] - The largest shareholder, Chongqing Pharmaceutical Health Industry Co., Ltd., holds 38.14% of shares, totaling 604,900,806 shares[15] - The company has a significant pledge situation, with 109,867,400 shares pledged by Chongqing Pharmaceutical Health Industry Co., Ltd.[15] Operating Costs and Expenses - Total operating costs amounted to ¥15,646,178,783.59, up from ¥14,590,776,932.08, reflecting a year-over-year increase of 7.2%[32] - Research and development expenses were reported at ¥76,038.11, a significant decrease from ¥3,265,576.96 in the previous period[32] - The company reported a total comprehensive income of ¥144,327,904.72, compared to ¥133,286,652.92 in the previous period, showing an increase of 8.0%[35]